Sodium Succinate

Stevens-Johnson Syndrome, Pemphigus, Ophthalmia, Sympathetic + 45 more

Treatment

5 FDA approvals

20 Active Studies for Sodium Succinate

What is Sodium Succinate

Methylprednisolone hemisuccinate

The Generic name of this drug

Treatment Summary

Methylprednisolone acetate is a medication that dissolves in water and is used to treat cardiac, allergic, and low oxygen emergencies.

Solu-medrol

is the brand name

image of different drug pills on a surface

Sodium Succinate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Solu-medrol

Methylprednisolone hemisuccinate

1959

89

Approved as Treatment by the FDA

Methylprednisolone hemisuccinate, also known as Solu-medrol, is approved by the FDA for 5 uses including Tuberculosis, Pulmonary and Tuberculosis, Pulmonary .

Tuberculosis, Pulmonary

Used to treat disseminated Pulmonary Tuberculosis (TB) in combination with null

Tuberculosis, Pulmonary

Used to treat fulminating Pulmonary Tuberculosis in combination with null

Tuberculous Meningitis

Used to treat Tuberculous Meningitis in combination with null

Tuberculosis, Meningeal

Used to treat Tuberculous Meningitis in combination with null

Subarachnoid Block

Used to treat Subarachnoid Block in combination with null

Effectiveness

How Sodium Succinate Affects Patients

Methylprednisolone sodium succinate is the sodium salt form of methylprednisolone. Both forms of the drug have the same effects, and are equally effective when taken in the same amounts.

When to interrupt dosage

The suggested dosage of Sodium Succinate is contingent upon the determined condition, such as Idiopathic Thrombocytopenic Purpura, Multiple Sclerosis and Pure Red Cell Aplasia. The measure fluctuates as per the mode of administration (e.g. Injection, powder, lyophilized, for solution - Intramuscular; Intravenous or Kit; Powder, for solution) specified in the table underneath.

Condition

Dosage

Administration

Mycosis Fungoides

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Polymyositis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Addison Disease

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Eosinophilic Pneumonia

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Dermatitis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Multiple Sclerosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Trichinosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Thrombocytopenia

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Sarcoidosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Acute Coryza

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Anemia, Hemolytic

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Craniotomy

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Thyroiditis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

exfoliative erythroderma

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

induction of Diuresis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Diuresis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Arthritis, Gouty

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Giant Cell Arteritis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Brain

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Dermatomyositis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Warnings

Sodium Succinate has three contraindications, therefore it should not be amalgamated with the conditions in the ensuing table.

Sodium Succinate Contraindications

Condition

Risk Level

Notes

intrathecal administration

Do Not Combine

Mycoses

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methylprednisolone Hemisuccinate may interact with Pulse Frequency

There are 20 known major drug interactions with Sodium Succinate.

Common Sodium Succinate Drug Interactions

Drug Name

Risk Level

Description

Aldesleukin

Major

The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Methylprednisolone hemisuccinate.

Corticorelin ovine triflutate

Major

The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone hemisuccinate.

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Methylprednisolone hemisuccinate.

1,10-Phenanthroline

Minor

The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Methylprednisolone hemisuccinate.

Aceclofenac

Minor

The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Aceclofenac.

image of a doctor in a lab doing drug, clinical research

Sodium Succinate Novel Uses: Which Conditions Have a Clinical Trial Featuring Sodium Succinate?

207 active clinical trials are examining the possibility of Sodium Succinate being an effective therapy for Palliative Care, Ulcerative Colitis and Eosinophilic Pneumonia.

Condition

Clinical Trials

Trial Phases

Metastatic Brain Tumors

56 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1, Phase 4

Psoriatic Arthritis

30 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Phase 4, Phase 2

Ulcerative Colitis

14 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1

Thrombocytopenia

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Berylliosis

0 Actively Recruiting

Adrenal Insufficiency

0 Actively Recruiting

Diuresis

0 Actively Recruiting

Anemia, Hemolytic

0 Actively Recruiting

Brain

0 Actively Recruiting

Brain

7 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Lupus Erythematosus

3 Actively Recruiting

Phase 4, Phase 1, Not Applicable

Crohn Disease

0 Actively Recruiting

Subarachnoid Block

0 Actively Recruiting

Stevens-Johnson Syndrome

1 Actively Recruiting

Phase 1

exfoliative erythroderma

0 Actively Recruiting

Arthritis, Gouty

0 Actively Recruiting

Multiple Sclerosis

0 Actively Recruiting

Craniotomy

0 Actively Recruiting

Addison Disease

0 Actively Recruiting

Sodium Succinate Reviews: What are patients saying about Sodium Succinate?

5

Patient Review

6/13/2014

Sodium Succinate for Contact Dermatitis

This injection was a literal life-saver. I had an allergic reaction that spread up to my shoulders and it was incredibly itchy. If it hadn't been treated, it could have closed off my airway. Thankfully, the allergy and accompanying itchiness disappeared within an hour of receiving this treatment.

5

Patient Review

6/13/2014

Sodium Succinate for Contact Dermatitis

I had an allergic reaction that was quickly getting out of control, but this injection stopped it in its tracks. I'm incredibly thankful for this life-saving medication.

4

Patient Review

12/19/2017

Sodium Succinate for Bronchitis

I was coughing uncontrollably when I went to Urgent Care. They took an X-ray of my lungs and listened to my lungs with a stethoscope. Then they prescribed me an inhaler and gave me a steroid injection (solu-medrol). So far, it's working great - I can breathe much better and the coughing is limited.

4

Patient Review

12/19/2017

Sodium Succinate for Bronchitis

The care I received at the urgent care center was great. They took an x-ray of my lungs and listened to my breathing with a stethoscope before giving me a prescription for an inhaler and injecting me with a steroid called solu-medrol. So far, it's been working well and I've been able to breathe much better with limited coughing.

2

Patient Review

5/18/2009

Sodium Succinate for Psoriasis

Unfortunately, this treatment only seemed to make my condition worse.

2

Patient Review

5/18/2009

Sodium Succinate for Psoriasis

Unfortunately, this treatment not only failed to improve my condition, but it seemed to make things worse.

1

Patient Review

3/4/2009

Sodium Succinate for Multiple Sclerosis

My wife started to experience psychosis after taking this medication as directed for five days. She ended up staying in the hospital for weeks, and I believe that the medicine is still affecting her years later. She is now in the late stages of MS with several stage 4 bed sores. There is no cure for this product, yet it's still on the market. Can someone help me with this?

1

Patient Review

1/12/2012

Sodium Succinate for Asthma

I experienced a lot of muscle pain and hallucinations while taking this medication.

1

Patient Review

3/4/2009

Sodium Succinate for Multiple Sclerosis

My wife and I took this medicine at home according to the recommended schedule. Once we completed the five days, my wife started having psychosis and had to stay in the hospital for weeks. I believe that the medicine is still affecting her after all these years because she is now in the late stages of MS with several stage 4 bed sores. There is no cure for this product yet, but it's still on the market. From what I understand, it can stay in your system for years. Can someone help me with this?

1

Patient Review

1/12/2012

Sodium Succinate for Asthma

This treatment caused me a lot of muscle pain and hallucinations. I would not recommend it to anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sodium succinate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is succinate used for?

"Succinate or succinic acid is involved in several chemical processes in the body and is used in supplements for symptoms related to menopause such as hot flashes and irritability. Succinate is also applied to the skin for arthritis and joint pain relief."

Answered by AI

Is sodium succinate an acid?

"It occurs as a white, crystalline powder and is soluble in water.

Sodium Succinate (Anhydrous) is the disodium salt of succinic acid. It occurs as a white, crystalline powder and is soluble in water. It can be used as a buffer for pH control in formulations."

Answered by AI

Clinical Trials for Sodium Succinate

Image of Princess Margaret Cancer Centre, University Health Network in Toronto, Canada.

Cognitive Stepped Care Program for Brain Cancer

18+
All Sexes
Toronto, Canada

Background: Cognitive symptoms are common and often severe in patients with brain metastases, significantly impacting their quality of life and ability to manage cancer care. Currently, there is no standard approach for routinely assessing and managing these symptoms in oncology clinics. Objective: This study aims to evaluate the feasibility, acceptability, and preliminary efficacy of the Cognitive Stepped Care Program (CSCP) in a Brain Metastases Clinic. Methods: This is a prospective, mixed-methods feasibility study involving patients with brain metastases, their caregivers, and clinic staff. Patients will undergo routine cognitive symptom screening using a standardized tool. Based on symptom severity, they will receive tiered interventions ranging from no support, to education materials, to computerized cognitive testing with individualized debrief, with group strategy training and/or neuropsychological consultation, as needed. Patients will complete questionnaires before and after the intervention regarding their symptoms and quality of life. Patients, caregivers and staff will provide their feedback about the intervention through questionnaires and interviews. Outcomes: Primary outcomes include feasibility and acceptability of the CSCP. Secondary outcomes include preliminary changes in cognitive symptoms, self-efficacy, and quality of life. Significance: This study will inform the potential integration of a structured cognitive support program into standard care for patients with brain metastases and may provide a model for similar interventions in other oncology settings.

Recruiting
Has No Placebo

Princess Margaret Cancer Centre, University Health Network

Image of McMaster Children's Hospital - Digestive Diseases Clinic in Hamilton, Canada.

Vancomycin for Ulcerative Colitis

18+
All Sexes
Hamilton, Canada

This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are: * Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks? * Is oral vancomycin safe and tolerable in this patient group? Participants will be compared to see if vancomycin works better than placebo. Participants will: * Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks * Have the option for 4 more weeks of open-label vancomycin after the blinded phase * Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks * Track treatment adherence and side effects The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.

Phase 2
Waitlist Available

McMaster Children's Hospital - Digestive Diseases Clinic

Neeraj Narula, MD

Have you considered Sodium Succinate clinical trials?

We made a collection of clinical trials featuring Sodium Succinate, we think they might fit your search criteria.
Go to Trials

Have you considered Sodium Succinate clinical trials?

We made a collection of clinical trials featuring Sodium Succinate, we think they might fit your search criteria.
Go to Trials
Image of Investigative Site in Beverly Hills, United States.

VENT-03 for Lupus

18 - 80
All Sexes
Beverly Hills, CA

The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are: * Does VENT-03 affect the activity and severity of CLE? * What side effects do participants have when taking VENT-03? Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE. Participants will: * Take VENT-03 or a placebo e for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks; * Visit the clinic once a month for checkups and tests.

Phase 2
Recruiting

Investigative Site (+9 Sites)

Ventus Therapeutics U.S., Inc.

Image of University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center in Cleveland, United States.

Whole Brain Radiotherapy for Brain Cancer

18+
All Sexes
Cleveland, OH

Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.

Phase 2
Waitlist Available

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Haley Perlow, MD

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.

Phase 4
Waitlist Available

Sunnybrook Health Sciences Centre (+4 Sites)

Have you considered Sodium Succinate clinical trials?

We made a collection of clinical trials featuring Sodium Succinate, we think they might fit your search criteria.
Go to Trials